Nature Medicine | Spoonful of Medicine

What’s in the mix for TB? The drugome suggests new cocktail solutions

By Stu Hutson The first-line regime of tuberculosis drugs has remained virtually unchanged for a half century. But instead of improving on these medications, some researchers say it’s time to scour the lists of already-approved drugs for other indications or start from scratch to curb the more than 1.7 million deaths from tuberculosis (TB) each year. In early November, for example, the New York–based TB Alliance announced the launch of a clinical trial to test a radically different drug cocktail. “We see this as a paradigm shift in methodology,” says Ann Ginsberg, the organization’s chief medical officer, “And it’s been 

BACK TO ARTICLE

Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.

BACK TO ARTICLE